Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats

The aim of this study was to characterize the role of the efflux transporter Mrp2 (Abcc2) in the pharmacokinetics of orally and intravenously administered pravastatin in rats. Eight Mrp2-deficient TR- rats and eight wild-type rats were given an oral dose of 20 mg/kg pravastatin. Four TR- animals and four wild-type animals were studied after intravenous administration of pravastatin ( 5 mg/kg). The TR- rats showed a 6.1-fold higher mean area under the plasma concentration-time curve (AUC) of pravastatin ( p < 0.001) after oral administration and a 4.7-fold higher AUC ( p < 0.01) after intravenous administration of pravastatin as compared with the wild-type animals. The mean systemic ( total) clearance of pravastatin was 4.6-fold higher (39.2 versus 8.50 l/h/ kg, p < 0.001) and the mean V 4.3-fold higher (14.1 versus 3.29 l/kg, p < 0.01) in the wild-type rats. The mean renal clearance of pravastatin in the TR- rats was 16.5-fold increased as compared with the wild-type animals (0.695 versus 0.042 l/h/ kg, p < 0.05). The increased systemic exposure to oral pravastatin in the TR- rats was associated with a greater inhibitory effect on 3-hydroxy-3-methylglutaryl CoA reductase, as shown by smaller lathosterol to cholesterol concentration ratios. These results suggest that the reduced biliary pravastatin excretion in the Mrp2-deficient TR- rats is partly compensated for by increased urinary excretion of pravastatin. Furthermore, intestinal Mrp2 does not appear to play a major role in the oral absorption of pravastatin in normal rats.